Sequoia Vaccines, Inc. (SQVI)

Sequoia Vaccines was planning to go public, but the IPO was withdrawn on May 5, 2025.
IPO Price Range
$8.00 - $10.00
Shares Offered
2,775,000
Deal Size
$24.98M
Chart not available yet
Data will show when the stock starts trading.
Market Cap79.45M
Revenue (ttm)n/a
Net Income (ttm)-4.49M
Shares Out 8.83M
EPS (ttm)-0.51
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Openn/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About SQVI

Sequoia Vaccines is a clinical stage pharmaceutical company developing a vaccine designed to prevent recurrent urinary tract infections (UTIs) and small molecules for treating cancers and bacterial infections. Our lead clinical candidate, SEQ-400, is a vaccine under investigation for the prevention of recurrent UTIs, which received fast track designation by the Food and Drug Administration in December 2017. We are planning a UTI observation trial in 2023 which will seek to identify and define a population of patients with culture-verified recur... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 5
Stock Exchange NYSEAMERICAN
Ticker Symbol SQVI
Full Company Profile

Financial Performance

Financial Statements

News

U.S. IPO Weekly Recap: Reinsurance And CAR T Therapies Lead A 3 IPO Week

Three IPOs and two SPACs debuted this week, while the pipeline got a boost from a flurry of initial filings. Oncology biotech CARGO Therapeutics priced at the bottom of the range to raise $281 million...

1 year ago - Seeking Alpha

Sequoia Vaccines Begins $20 Million IPO Effort

Sequoia Vaccines, Inc. has filed for a $20 million IPO to raise funds for the development of its vaccine for urinary tract infections and treatment for ovarian cancer. The company's lead drug has show...

1 year ago - Seeking Alpha

Vaccine developer Sequoia Vaccines files for a $20 million IPO

Sequoia Vaccines, a Phase 1 biotech developing a vaccine for recurrent UTIs and small molecules for cancers, filed on Monday with the SEC to raise up to $20 million in an initial public offering.

1 year ago - Renaissance Capital

Sequoia Vaccines IPO Registration Document (S-1)

Sequoia Vaccines has filed to go public with an IPO on the NYSE American.

1 year ago - SEC